Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 45: 1141-1147, 1999;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauck, M.
Right arrow Articles by März, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nauck, M.
Right arrow Articles by März, W.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 1999;45:1141-1147.)
© 1999 American Association for Clinical Chemistry, Inc.


Articles

Rapid, Homogeneous Genotyping of the 4G/5G Polymorphism in the Promoter Region of the PAI1 Gene by Fluorescence Resonance Energy Transfer and Probe Melting Curves

Markus Naucka, Heinrich Wieland and Winfried März

Division of Clinical Chemistry, Department of Medicine, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg i. Br., Germany.
a Author for correspondence. Fax 49-761-270 3444; e-mail msnauck{at}med1.ukl.uni-freiburg.de


   Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Background: Many studies have convincingly shown that survivors of myocardial infarction have impaired fibrinolytic activity because of increased concentrations of plasma plasminogen activator inhibitor-1 (PAI-1). A single guanosine insertion/deletion polymorphism in the promoter region of the PAI1 gene, commonly called 4G/5G, has been shown to be associated with plasma PAI-1 activity. Our aim was to develop and validate a homogeneous assay for rapid genotyping of the 4G/5G polymorphism.

Methods: In this report we present a single-tube method for genotyping of the 4G/5G polymorphism that combines both rapid-cycle PCR with real-time monitoring of the amplification process and generation of allele-specific fluorescent probe melting profiles on the LightCyclerTM. Two fluorescently labeled hybridization probes recognizing adjacent sequences in the amplicon were present in the reaction mixture. The shorter detection probe spanned the polymorphic site, perfectly matching the 5G allele. After annealing, the fluorophores were in resonance energy transfer, providing real-time monitoring of the amplification process. At the completion of the PCR, fluorescence was monitored as the temperature increased through the Tm of the probe/product duplex, and a characteristic melting profile for each genotype was obtained.

Results: With this method, 32 samples were genotyped within 30 min without the need of any post-PCR sample manipulation. The genotypes of 100 DNA samples determined with the LightCycler were identical to those obtained with conventional PCR and restriction fragment length analysis.

Conclusion: The genotyping of the 4G/5G polymorphism with the LightCycler is a rapid, reliable method that is suitable for typing both small and large numbers of samples.© 1999 American Association for Clinical Chemistry


   Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Several prospective studies have documented that the fibrinolytic capacity is an important determinant of the risk of thrombosis (1)(2)(3)(4). Impaired fibrinolysis may result from increased concentrations of the principal inhibitor of the fibrinolytic system, plasminogen activator inhibitor-1 (PAI-1).1

PAI-1 is a 50-kDa glycoprotein belonging to the serine protease superfamily (serpins) (5). It inhibits both tissue-type and urokinase-type plasminogen activators and is considered as the primary regulator of plasminogen activation (6). An increased plasma concentration of PAI-1 is a marker for first and recurrent myocardial infarction in young patients (1)(2) and for ischemic events in individuals with preexisting atherosclerosis (7). PAI-1 concentrations relate to the degree and severity of atherosclerotic lesions (8), and PAI-1 may play a role in the pathogenesis of cerebrovascular disease and venous thromboembolism (9)(10).

The genetic and environmental determinants of PAI-1 expression are still incompletely understood. It has been postulated that PAI-1 responses to different stimuli in vivo may be mediated by changes of the rate of gene transcription and that sequence elements within the promoter region control this response. A common single nucleotide insertion/deletion polymorphism in the PAI1 promoter (4G/5G) has been identified 675 bp upstream from the start of transcription. This polymorphism produces two alleles containing either four or five sequential guanosines (G) (11)(12). The 4G/5G polymorphism has been related to circulating PAI-1 concentrations in healthy subjects, young patients with myocardial infarction, and patients with non-insulin-dependent diabetes, with subjects homozygous for the 4G (deletion) allele having the highest PAI-1 concentrations (11)(12)(13)(14). In vitro studies have shown increased gene transcription associated with the 4G allele (11)(12). This provides a potential mechanism for the increase in PAI-1 concentrations with the number of 4G alleles seen in vivo. Therefore, genotyping of this polymorphism may become relevant to risk assessment and to the selection and dosing of patients being treated with anticoagulant and fibrinolytic agents, in particular with tissue plasminogen activator.

We present here a single-step method for genotyping of the 4G/5G polymorphism of the PAI1 gene that uses rapid-cycle PCR and subsequent analysis with resonance energy transfer probes on a thermal cycler with real-time fluorescence monitoring (15). After completion of the amplification process, the fluorescence signal is used to analyze the allele-specific melting behavior of the fluorophore-labeled hybridization probe. This is the first report demonstrating that not only single-base substitutions but also single-base insertions/deletions within PCR products can be readily identified by their characteristic melting behavior by the use of sequence-specific fluorescently labeled oligonucleotide hybridization probes.


   Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
specimen collection
Genomic DNA was isolated from whole blood or buffy coats with the QIAamp Blood Kit (Qiagen). The DNA was resuspended at a concentration of 100 mg/L in distilled water or 10 mmol/L Tris, pH 7.4, containing 0.1 mmol/L EDTA. DNA that was not used immediately was stored at 2–8 °C for not longer than 7 days or frozen at -20 °C.

mutation detection using fluorescence resonance energy transfer
Fluorescence monitoring using hybridization probes is based on the concept that a fluorescence signal is generated if fluorescence resonance energy transfer (FRET) occurs between two adjacent fluorophores (16). The first hybridization probe, which is labeled with fluorescein as donor fluorophore on its 3' end, can hybridize in close proximity to a second hybridization probe that is labeled with the acceptor fluorophore LightCyclerTM Red 640 at its 5' end and is blocked from extension at its 3' terminus. The fluorescein is excited by a LED light source and transfers energy to the acceptor fluorophore. The acceptor fluorophore then emits light of a longer wavelength that can be measured with a photodiode. This detection strategy allows monitoring of the amplification process on a per-cycle basis because the intensity of the FRET signal depends on the amount of specific PCR product generated. Even more important, genotyping using two hybridization probes is possible with a shorter "detection probe" that spans the polymorphic site and a longer "anchor probe" that recognizes an adjacent sequence. The greater stability of the longer anchor probe causes the detection probe to melt off the template at a lower temperature so that polymorphic alleles can be distinguished by the melting temperature (Tm) of the detection probe. Continuous monitoring of the fluorescence as the temperature is raised from annealing to denaturation produces a sharp decrease in fluorescence when the detection probe dissociates from the template.

design of primers and fluorogenic probes
The primer 5'-AGCCAGACAAGGTTGTTGACAC-3' (nucleotides -741 to -720, relative to the transcription start site) and the primer 5'-CAGAGGACTCTTGGTTTTCCC-3' (nucleotides -628 to -607, relative to the transcription start site) were used to amplify, respectively, a 134- or a 135-bp fragment of the human PAI1 gene that harbors the polymorphic site 675 nucleotides upstream from the start of transcription (GenBank locus HSPAI11) (17). The amplification primers were synthesized by standard phosphoramidite chemistry (MWG-Biotech).

The detection probe was a 18-mer oligonucleotide, labeled at the 3' end with fluorescein. The sequence 5'-TGACTCCCCCACGTGTCC-3' is complementary to the leading strand of the 5G allele (underlined nucleotides; Fig. 1 ). The anchor probe (5'-ACTCTCTCTGTGCCCCTGAGGGCTCT-3') was a 26-mer labeled with LightCycler Red 640 at its 5' end and modified at the 3' end by phosphorylation to block extension. The anchor probe binds at a distance two bases 3' from the detection probe. Both fluorophore-labeled probes were synthesized and purified by reversed-phase HPLC by TipMolBiol.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 1. Relative orientation of the fluorophore-labeled anchor and detection probes.

The detection probe spanning the polymorphic region at position -675 in the promoter of the PAI1 gene upstream from the start of transcription is labeled at the 3' end with fluorescein (FITC). The anchor probe, labeled with LightCycler Red 640 (LCRed 640) at its 5' end, is phosphorylated at its 3' end to block extension and binds at a distance two nucleotides 3' from the detection probe. During annealing, both probes hybridize to their complementary sequences of the leading strand of the promoter. The proximity of the LightCycler Red 640 and fluorescein labels produces FRET, which is monitored at the end of each annealing step during PCR and continuously throughout recording the melting curve. The 4G/5G polymorphism is the result of a single-base insertion/deletion polymorphism, giving rise to two alleles containing either four or five guanosines in a row. This polymorphism creates a mismatch between the leading strand of the 4G allele and the detection probe, which destabilizes the hybrid and lowers the probe melting temperature. In contrast, complete matching of the detection probe and the leading strand of the 5G allele increases the melting temperature of the hybrid.

fluorescence protocol
The analysis was carried out on a LightCycler (Roche Molecular Biochemicals). PCR was performed by rapid cycling in a reaction volume of 10 µL with 0.3 µmol/L each primer, 0.2 µmol/L anchor and detection probes, and 50 ng of genomic DNA. As a reaction buffer, the LightCycler DNA Master Hybridization Probes buffer from Roche Molecular Biochemicals was used (cat. no. 2015102). This buffer is provided as a 10-fold stock solution containing nucleotides, Thermus aquaticus DNA polymerase, and 10 mmol/L Mg2+. The final Mg2+ concentration in the reaction mixture was adjusted to 4 mmol/L. The samples were loaded into glass capillary cuvettes (cat. no. 1909339; Roche Molecular Biochemicals) and centrifuged to place the sample at the capillary tip before capping. After an initial denaturation step at 94 °C for 45 s, amplification was performed using 50 cycles of denaturation (94 °C for 0 s), annealing (57 °C for 5 s), and extension (72 °C for 2 s). The temperature transition rates were programmed at 20 °C/s from denaturation to annealing, 3 °C/s from annealing to extension, and 20 °C/s from extension to denaturation. Fluorescence was measured at the end of the annealing period of each cycle to monitor amplification. After amplification was complete, a final melting curve was recorded by cooling the reaction mixture to 45 °C at 10 °C/s, holding it at 45 °C for 3 min, and then slowly heating it to 75 °C at 0.2 °C/s. Fluorescence was measured continuously during the slow temperature ramp to monitor the dissociation of the fluorescein-labeled detection probe. The fluorescence signal (F) was plotted in real time against temperature (T) to produce melting curves for each sample (F vs T). Melting curves were then converted to derivative melting curves by plotting the negative derivative of the fluorescence with respect to temperature against temperature [-(dF/dT) vs T]. The entire process took ~30 min with no separate manipulation of the product necessary.

genotyping by allele-specific restriction enzyme site analysis
For confirmation of genotypes, allele-specific restriction enzyme site analysis (ASRA) was performed as described previously (18). This protocol uses a modified upstream primer producing a BslI cutting site with the 5G allele but not with the 4G allele. In brief, a 99- or 98-bp fragment, depending on the promoter allele present, was amplified from genomic DNA using the primers described by Margaglione et al. (18). Amplifications were performed in volumes of 50 µL containing 100 ng of genomic DNA, 0.8 µmol/L each primer, 200 µmol/L each deoxyribonucleotide, 10 mmol/L Tris-HCl, pH 8.3, 1.5 mmol/L MgCl2, 50 mmol/L KCl, 0.1 g/L gelatin, and 1 U of Thermus aquaticus DNA polymerase (Roche Molecular Biochemicals). The protocol included an initial denaturation step at 94 °C for 2 min, followed by 40 cycles of 20 s of denaturation at 94 °C, 20 s of annealing at 60 °C, and 20 s of elongation at 72 °C. Thermocycling was carried out on a conventional programmable thermocycler (UNO II; Biometra), followed by a final elongation step of 72 °C for 5 min. Aliquots (10 µL) of the PCR mixture were then digested for 4 h at 55 °C with 5 U of BslI, using the restriction buffer recommended by the manufacturer (New England Biolabs). The resulting fragments (77 and 22 bp for the 5G allele, and 98 bp for the 4G allele) were electrophoresed on 3.5% GTG agarose (FMC Bioproducts), visualized with 0.5 mg/L ethidium bromide, and examined under ultraviolet illumination.


   Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Fifty cycles of amplification were performed with genomic DNA of each genotype and a template-free control, using the FRET detection system outlined in Fig. 1Up . When fluorescence was measured at the end of each annealing phase, the fluorescence signal increased as product accumulated. Under our conditions, the fluorescence signal appeared above background after 20 cycles (Fig. 2 ). No increase in fluorescence signal was observed in the absence of template (Fig. 2 , curve D).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 2. Intensity of the fluorescence signal (F) vs cycle number.

A 134- or 135-bp fragment of the PAI1 gene was amplified from genomic DNA of three different genotypes: homozygous for the 4G allele (curve A), heterozygous (curve B), and homozygous for the 5G allele (curve C). Amplification of a no-template control (curve D) was also attempted. The fluorescence signal was acquired once each cycle at the end of the annealing period.

The process of hybridization and melting of the detection probe to the target was monitored by melting curve analysis. Melting of the sample homozygous for the 4G allele produced a rapid decrease in fluorescence at 56–57 °C. In contrast, in the sample homozygous for the 5G allele, the transition occurred at 63–64 °C. The heterozygous sample exhibited two distinct decreases in fluorescence, corresponding to the presence of amplicons derived from both alleles. Peaks were obtained at the respective melting temperatures by plotting the negative derivative of the fluorescence signal with temperature vs temperature [-(dF/dT) vs T]. Accordingly, the melting peak of the sample homozygous for the 5G allele was at 64 °C (Fig. 3 , curve C), whereas in the sample homozygous for the 4G allele, a melting peak was obtained at 57 °C (Fig. 3 , curve A). The heterozygous sample contained both types of targets and thus generated both peaks (Fig. 3 , curve B). With different samples showing different amplification efficiencies, the derivative melting curves were highly reproducible, with melting peaks differing by <1.5 °C for the same allele, allowing easy and unambiguous assignment of genotypes to the respective melting curves.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 3. Genotyping of the PAI1 promoter with an allele-specific fluorescent probe by derivative melting curve plots.

Following amplification, a melting analysis was performed immediately. Data of the fluorescence signal were obtained during the melting transition of the fluorescein-labeled detection probe from the amplified fragment. The temperature transition was programmed at 0.2 °C/s, with continuous fluorescence acquisition at maximum speed for each sample from 45 to 75 °C. Fluorescence data were converted to derivative melting curves by plotting the negative derivative of the fluorescence with respect to temperature against temperature [-(dF/dT) vs T]. The derivative melting curve is plotted for a sample homozygous for the 4G allele (curve A), a heterozygous sample (curve B), and a sample homozygous for the 5G allele (curve C). Melting analysis of a no-template control (curve D) was also performed.

To evaluate the reliability of the fluorescence genotyping, 100 human DNA samples were genotyped for the 4G/5G polymorphism by both the primer-mediated ASRA and the fluorescence method. The PCR products and fragments obtained by ASRA were of the expected sizes (Fig. 4 ), and the genotypes determined with both methods were in 100% concordance. Thirty-two samples were homozygous for the 4G allele, 49 were heterozygous, and 19 were homozygous for the 5G allele. The genotyping of the 100 samples on the LightCycler was completed within 2 h, whereas the ASRA protocol took 8 h and required several manual sample processing steps.



View larger version (44K):
[in this window]
[in a new window]
 
Figure 4. Genotyping of the 4G/5G polymorphism by primer-mediated ASRA.

A representative ethidium bromide-stained 3.5% agarose gel containing PCR fragments generated on the LightCycler for fluorescent genotyping (lanes 1–3) and undigested and digested PCR products (lanes 4–9) for typing the 4G/5G polymorphism with ASRA according to the method of Margaglione et al. (18) is shown. Lanes 4–6 contain the undigested 98- to 99-bp PCR product of three samples corresponding to the three possible allelic combinations. Lanes 7–9 contain the PCR fragments digested with BslI that allow genotyping of the 4G/5G polymorphism. The different genotypes were loaded in the following manner: 4G/4G (lane 7), 4G/5G (lane 8), 5G/5G (lane 9). Lanes M contain a 100-bp DNA size marker (Life Technologies).

Comparison of the costs for reagents and disposable material showed that both methods are about equally expensive, with costs of approximately $2.00 (US) per typing reaction.


   Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Circulating concentrations of PAI-1 may determine vascular risk through two separate but related mechanisms. Fibrin deposition is an invariable feature of atherosclerotic plaques, and high local concentrations of PAI-1 may theoretically produce increased fibrin deposition and plaque formation. This possibility is supported by data showing increased circulating PAI-1 in subjects with coronary atheroma (19). Apart from that, acute myocardial infarction is usually associated with thrombosis at the site of ruptured atherosclerotic plaques (20). Increased concentrations of PAI-1 may promote coronary thrombosis and occlusion by creating a prothrombotic state.

Because there is some evidence that PAI-1 release from atherosclerotic lesions is increased as part of an acute-phase response, it is also possible that the increased PAI-1 seen in several studies may result from, rather than lead to, atherosclerosis or thrombosis (21). Furthermore, an association between PAI-1 concentrations and coronary artery disease may be concealed by the close correlation between PAI-1 concentrations and other established risk factors, such as insulin resistance (22)(23). Furthermore, measurement of PAI-1 activity and PAI-1 antigen is complicated by several preanalytical requirements. For example, rapid sample handling and quick freezing of the samples is necessary because PAI-1 is a labile molecule with a half-life of functional activity of ~4 h under physiological conditions (6). If PAI-1 antigen is to be measured, precautions must be taken to avoid release of PAI-1 from platelets. Generally, the time for blood sampling must be standardized because of the diurnal fluctuation of fibrinolytic activity (24). Therefore, the association of the 4G allele with increased plasma PAI-1 might be more reliable and robust as a predictor of the thrombotic risk than plasma concentrations. In addition, in the general population, plasma concentrations have a continuous distribution, which makes it difficult to establish cutoff values that can identify individuals at risk.

The growing evidence that the PAI-1 concentrations in the circulation are related to the common 4G/5G polymorphism in the promoter of the PAI1 gene has opened the possibility of using PAI1 genotype as a marker for life-long exposure to differing PAI-1 concentrations. Furthermore, the determination of the PAI1 polymorphism based on the PCR is simple in terms of preanalytical precautions and requires only a small number of nucleated cells.

PCR with allele-specific oligonucleotide hybridization (11)(14)(25), amplification with sequence-specific primers (26)(27)(28)(29), ASRA (18)(30), and single-strand conformation polymorphism (31) have been used to genotype the PAI1 promoter polymorphism. PCR with allele-specific oligonucleotide dot-blot hybridization is time-consuming, and the conditions for allele-specific hybridization based on a single-base deletion/insertion are crucial. The method may be affected by variations of the quality of the PCR products and is sensitive to small changes of the hybridization conditions. PCR with sequence-specific primers is an increasingly popular method for genotyping biallelic systems. However, most protocols to date require the use of separate tubes for specifically amplifying each allele, adding time and expense. In addition to the inherent risk of false-positive amplification, the performance of the sequence-specific primers must be verified by the amplification of internal control fragments. Techniques based on ASRA need PCR conditions of sufficient specificity to produce a clean amplification product that can be enzymatically digested and analyzed by electrophoresis. Furthermore, the procedure may be complicated by incomplete digestion of the amplicons.

The potential benefits of homogeneous detection systems have long been recognized (32), and recently several fluorescence-based methods for typing biallelic systems have been described that improve sample throughput (33)(34)(35)(36)(37). In the present study, we used probe hybridization and FRET to monitor product accumulation during rapid-cycle DNA amplification and to determine PAI1 promoter genotypes by melting-curve analysis of the amplified fragment on the LightCycler. This protocol allows fluorescence genotyping of 32 samples in <30 min without any need for enzyme digestion or electrophoresis. Because this method is performed in a closed system with no postamplification processing, potential problems with sample tracking errors and end-product contamination are eliminated. The robustness and reliability of the fluorescence genotyping was well documented by the complete concordance of 100 genotypes determined with both the conventional restriction fragment length analysis and the LightCycler protocol.

This new method combines simple sample processing and rapid analysis; it therefore affords both high-throughput genotyping and rapid results. Furthermore, because hands-on time is short, this method permits PAI1 genotyping in a very economical manner. Compared with published fluorescence protocols applied on the ABI 7700 (35)(36) or the ABI 5700 from Perkin-Elmer (37), the analytical runs on the LightCycler are about three times faster. On the other hand, the instruments from Perkin-Elmer allow the simultaneous processing of three times as many samples. Although the sample throughput of both systems is similar, the faster processing of the LightCycler allows more flexibility in the use of the instrument.

Similar to the conventional use of allele-specific oligonucleotide probes in mutation detection, melting curve analysis depends on the thermal stability difference between matched and mismatched DNA duplexes. Many years ago, Wallace et al. (38) showed that single-base mismatches lowered the melting temperature of oligonucleotide probes by several degrees Celsius. The extent of destabilization depends on the duplex length, the particular mismatch, the nearest neighbor environment, and the position of the mutation site relative to the probe (39). The molecular characteristics of the 4G/5G polymorphism is different from single-base mismatches in that a single guanosine is inserted or deleted, giving rise to alleles with four or five guanosines, respectively. By using an 18-mer detection probe that is fully complementary to the leading strand of the 5G allele, we achieved a Tm shift between both alleles of 7.0 °C. This difference in Tm between homoduplex and heteroduplex is in the range reported for single-base mismatches in 18-mers (40). This indicates that the design of our detection probe was appropriate to discriminate between genotypes at that locus. Most likely, by annealing to the 4G allele, the hybridization probe is forced into a bend, with one cytosine being unable to hybridize and weakened hydrogen bonds in its neighborhood.

Our results also suggest that other base insertion/deletion polymorphisms with potential relevance to human disease can be conveniently genotyped with a homogeneous assay using fluorescence-labeled hybridization probes (41)(42).

To date, three single-step genotyping methods using the LightCycler have been described. The first two applications, designed for detection of the factor V Leiden mutation and the C677T point mutation in the methylenetetrahydrofolate reductase gene, used one Cy5-labeled primer and one fluorescein-labeled hybridization probe with asymmetric amplification of the target sequence. In contrast, Bernard et al. (43) in a more recent work developed an assay for homogeneous multiplex genotyping of hemochromatosis mutations that uses two pairs of hybridization probes binding to internal sequences of two fragments amplified simultaneously. We used a similar approach by also using a pair of fluorophore-labeled probes that hybridize to the same strand internal to an unlabeled primer set. The results of Bernard et al. as well as ours document that an internal hybridization probe pair works equally well. Because the synthesis of labeled primers is known to be more difficult than the end-labeling of internal probes, the probe pair system may be more flexible and cost-effective.

In summary, we developed a homogeneous (closed tube) assay for rapid genotyping of the 4G/5G promoter polymorphism of the PAI1 gene on the LightCycler that allows both real-time monitoring of the amplification process and allele-specific analysis of the probe melting curves at completion of the amplification. Genotyping of 32 samples is accomplished within 30 min, making this method ideally applicable to PAI1 typing in both small and large numbers of patients.


   Acknowledgments
 
We gratefully acknowledge the excellent technical assistance of Ulrike Stein and Sabine von Karger.


   Footnotes
 
1 Nonstandard abbreviations: PAI-1, plasminogen activator inhibitor-1; FRET, fluorescence resonance energy transfer; and ASRA, allele-specific restriction enzyme site analysis.


   References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 

  1. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563. [Abstract]
  2. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9. [Web of Science][Medline] [Order article via Infotrieve]
  3. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-1079. [Web of Science][Medline] [Order article via Infotrieve]
  4. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641. [Abstract/Free Full Text]
  5. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986;5:2539-2544. [Web of Science][Medline] [Order article via Infotrieve]
  6. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease [Review]. Thromb Haemost 1995;74:71-76. [Web of Science][Medline] [Order article via Infotrieve]
  7. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 1993;13:1412-1417. [Abstract/Free Full Text]
  8. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study Atherosclerosis Risk in Communities Study. Circulation 1995;91:284-290. [Abstract/Free Full Text]
  9. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67-72. [Web of Science][Medline] [Order article via Infotrieve]
  10. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998;79:975-979. [Web of Science][Medline] [Order article via Infotrieve]
  11. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-10745. [Abstract/Free Full Text]
  12. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-1855. [Abstract/Free Full Text]
  13. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995;44:37-42. [Abstract]
  14. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995;74:837-841. [Web of Science][Medline] [Order article via Infotrieve]
  15. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-181. [Web of Science][Medline] [Order article via Infotrieve]
  16. Morrison LE. Detection of energy transfer and fluorescence quenching. Kricka LJ eds. Nonisotopic DNA probe techniques 1992:117-133 Academic Press San Diego. .
  17. Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988;176:609-616. [Web of Science][Medline] [Order article via Infotrieve]
  18. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing [Letter]. Thromb Haemost 1997;77:605-606. [Web of Science][Medline] [Order article via Infotrieve]
  19. Anonymous. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8–17..
  20. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-1140. [Abstract]
  21. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992;89:6998-7002. [Abstract/Free Full Text]
  22. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-278. [Web of Science][Medline] [Order article via Infotrieve]
  23. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis [Review]. Diabetologia 1991;34:457-462. [Web of Science][Medline] [Order article via Infotrieve]
  24. Kluft C, Verheijen JH, . The Leiden Fibrinolysis Working Party. Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990;4:155-161.
  25. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Biol 1997;17:755-759. [Abstract/Free Full Text]
  26. Falk G, Almquist A, Nordenhem A, Svensson H, Wimann B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995;9:170-174. [Web of Science]
  27. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995;74:1032-1034. [Web of Science][Medline] [Order article via Infotrieve]
  28. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Biol 1997;17:33-37. [Abstract/Free Full Text]
  29. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Di Bitondo R, Donati MB, Iacoviello L. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998;79:354-358. [Web of Science][Medline] [Order article via Infotrieve]
  30. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Biol 1998;18:152-156. [Abstract/Free Full Text]
  31. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62. [Abstract/Free Full Text]
  32. Chehab FF, Kan YW. Detection of specific DNA sequences by fluorescence amplification: a color complementation assay. Proc Natl Acad Sci U S A 1989;86:9178-9182. [Abstract/Free Full Text]
  33. Livak KJ, Marmaro J, Todd JA. Towards fully automated genome-wide polymorphism screening [Letter]. Nat Genet 1995;9:341-342. [Web of Science][Medline] [Order article via Infotrieve]
  34. Kyger EM, Krevolin MD, Powell MJ. Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. Anal Biochem 1998;260:142-148. [Web of Science][Medline] [Order article via Infotrieve]
  35. Chen X, Livak KJ, Kwok PY. A homogeneous, ligase-mediated DNA diagnostic test. Genome Res 1998;8:549-556. [Abstract/Free Full Text]
  36. Kostrikis LG, Tyagi S, Mhlanga MM, Ho DD, Kramer FR. Spectral genotyping of human alleles. Science 1998;279:1228-1229. [Free Full Text]
  37. Germer S, Higuchi R. Single-tube genotyping without oligonucleotide probes. Genome Res 1999;9:72-78. [Abstract/Free Full Text]
  38. Wallace RB, Johnson MJ, Hirose T, Miyake T, Kawashima EH, Itakura K. The use of synthetic oligonucleotides as hybridization probes. II. Hybridization of oligonucleotides of mixed sequence to rabbit beta-globin DNA. Nucleic Acids Res 1981;9:879-894. [Abstract/Free Full Text]
  39. Wetmur JG. DNA probes. applications of the principles of nucleic acid hybridization [Review]. Crit Rev Biochem Mol Biol 1991;26:227-259. [Web of Science][Medline] [Order article via Infotrieve]
  40. Werntges H, Steger G, Riesner D, Fritz HJ. Mismatches in DNA double strands: thermodynamic parameters and their correlation to repair efficiencies. Nucleic Acids Res 1986;14:3773-3790. [Abstract/Free Full Text]
  41. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055-13060. [Abstract/Free Full Text]
  42. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc Natl Acad Sci U S A 1993;90:4562-4566. [Abstract/Free Full Text]
  43. Bernard PS, Ajioka RS, Kushner JP, Wittwer CT. Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes. Am J Pathol 1998;153:1055-1061. [Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
Nucleic Acids ResHome page
G. Amicarelli, E. Shehi, G. M. Makrigiorgos, and D. Adlerstein
FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations
Nucleic Acids Res., October 11, 2007; (2007) gkm809v1.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
G. Pont-Kingdon and E. Lyon
Direct molecular haplotyping by melting curve analysis of hybridization probes: beta 2-adrenergic receptor haplotypes as an example
Nucleic Acids Res., June 3, 2005; 33(10): e89 - e89.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
Y. Jiang, T. Ellis, and A. R. Greenlee
Genotyping Parkinson Disease-Associated Mitochondrial Polymorphisms
Clin. Med. Res., May 1, 2004; 2(2): 99 - 106.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Olman, K. E. White, L. B. Ware, W. L. Simmons, E. N. Benveniste, S. Zhu, J. Pugin, and M. A. Matthay
Pulmonary Edema Fluid from Patients with Early Lung Injury Stimulates Fibroblast Proliferation through IL-1{beta}-Induced IL-6 Expression
J. Immunol., February 15, 2004; 172(4): 2668 - 2677.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. K. Tong and J. Ju
Single nucleotide polymorphism detection by combinatorial fluorescence energy transfer tags and biotinylated dideoxynucleotides
Nucleic Acids Res., March 1, 2002; 30(5): e19 - e19.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Ruiz, G. Antinolo, I. Marcos, and S. Borrego
Novel Technique for Scanning of Codon 634 of the RET Protooncogene with Fluorescence Resonance Energy Transfer and Real-Time PCR in Patients with Medullary Thyroid Carcinoma
Clin. Chem., November 1, 2001; 47(11): 1939 - 1944.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
F. Somogyvari, Z. Szolnoki, J. Marki-Zay, and L. Fodor
Real-Time PCR Assay with Fluorescent Hybridization Probes for Exact and Rapid Genotyping of the Angiotensin-converting Enzyme Gene Insertion/Deletion Polymorphism
Clin. Chem., September 1, 2001; 47(9): 1728 - 1729.
[Full Text] [PDF]


Home page
Genome ResHome page
M. V. Myakishev, Y. Khripin, S. Hu, and D. H. Hamer
High-Throughput SNP Genotyping by Allele-Specific PCR with Universal Energy-Transfer-Labeled Primers
Genome Res., January 1, 2001; 11(1): 163 - 169.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
N. von Ahsen, M. Oellerich, and E. Schutz
DNA Base Bulge vs Unmatched End Formation in Probe-based Diagnostic Insertion/Deletion Genotyping: Genotyping the UGT1A1 (TA)n Polymorphism by Real-Time Fluorescence PCR
Clin. Chem., December 1, 2000; 46(12): 1939 - 1945.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. D. Press
Detection of Prevalent Genetic Alterations Predisposing to Hemochromatosis and Other Common Human Diseases
Clin. Chem., October 1, 2000; 46(10): 1526 - 1528.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
P. S. Bernard and C. T. Wittwer
Homogeneous Amplification and Variant Detection by Fluorescent Hybridization Probes
Clin. Chem., February 1, 2000; 46(2): 147 - 148.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauck, M.
Right arrow Articles by März, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nauck, M.
Right arrow Articles by März, W.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Hemostasis and Thrombosis


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS